Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Colonoscopy | Research

The impact of COVID-19 on national program of colorectal cancer screening in Tehran, Iran: a multicenter study

Authors: Amir Sadeghi, Hamid Asadzadeh Aghdaei, Mohammad Amin Khalafi, Ehsan Nazemalhosseini-Mojarad, Pardis Ketabi Moghadam, Mohammad-Reza Sohrabi

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

The COVID-19 pandemic has affected all aspects of the healthcare system, including prevention, treatment, rehabilitation of diseases and health education; access to essential therapies; allocation of finance & facilities to health issues, and governance of diseases, including COVID-19 and other diseases. Consequently, the burden of COVID-19 was not only attributable to the multiorgan involvement and detailed presentation of the disease but also to the inadequate management of other diseases resulting from the exclusive allocation of resources and medical personnel to the pandemic crisis. Over the mentioned period, one observed deficiency was the lack of public and official favor for conventional screening protocols. To this end, this study aims to evaluate the impact of the COVID-19 pandemic on colorectal cancer (CRC) screening protocols at Shahid Beheshti University of Medical Sciences in Tehran, Iran, in an effort to identify individuals at risk for CRC and provide them with intensive screening and therapy.

Methods

This is an observational study comparing the number of candidates for CRC screening referred to primary, secondary, and tertiary health-care centers under supervision of Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran in a 2-year interval before and after COVID-19 pandemics. Patients with intermediate- and high-risk criteria for colorectal cancer were included in the study and were screened by fecal immunochemical test. Patients with positive or indeterminate fecal test results were further evaluated with colonoscopy in research institute for gastroenterology and liver diseases where is a tertiary referral center for CRC screening. Finally, the decrease percentage of screening tests and endoscopic findings during the pandemic period compared to pre-pandemic period was calculated and interpreted.

Results

A significant decrease in the number of performed fecal immunochemical tests (FITs), referred positive FITs, and referred patients with positive alarm signs to the Research Institute of Gastroenterology and Liver Diseases (RIGLD) center inevitably led to a considerable decrease in the number of endoscopic findings, including high-risk adenomas, sessile serrated polyps, and even early-stage colorectal cancers (CRCs).

Conclusion

The disruption of screening protocols caused by the COVID-19 pandemic appears to increase the number of patients with high-grade and end-stage CRCs referred in the near future.
Appendix
Available only for authorised users
Literature
14.
go back to reference Fancellu A, Veneroni S, Santoru A, Meloni A, Sanna V, Ginesu GC, et al. How the COVID-19 pandemic has affected the colorectal cancer screening in Italy: a minireview. World J Gastrointest Oncol. 2022;14(8):1490–8.CrossRefPubMedPubMedCentral Fancellu A, Veneroni S, Santoru A, Meloni A, Sanna V, Ginesu GC, et al. How the COVID-19 pandemic has affected the colorectal cancer screening in Italy: a minireview. World J Gastrointest Oncol. 2022;14(8):1490–8.CrossRefPubMedPubMedCentral
Metadata
Title
The impact of COVID-19 on national program of colorectal cancer screening in Tehran, Iran: a multicenter study
Authors
Amir Sadeghi
Hamid Asadzadeh Aghdaei
Mohammad Amin Khalafi
Ehsan Nazemalhosseini-Mojarad
Pardis Ketabi Moghadam
Mohammad-Reza Sohrabi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11111-x

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine